Abstract
Matrix metalloproteinase-13 (MMP13) is frequently overexpressed across various human cancers and is associated with poor clinical outcomes. This study provides a comprehensive pan-cancer analysis of MMP13, exploring its expression patterns, prognostic significance, and relationship with the tumor microenvironment. Our findings demonstrate that MMP13 is a potent driver of carcinogenesis, particularly through the epithelial-mesenchymal transition (EMT) pathway. Furthermore, clinical validation using ELISA highlights serum MMP13 as a highly accurate, non-invasive diagnostic biomarker, outperforming several established clinical markers in breast, head and neck, and lung cancers.
Introduction
The early detection of cancer remains a significant challenge, often requiring invasive biopsies. There is an urgent need for sensitive, non-invasive biomarkers for liquid biopsy. Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix remodeling, playing pivotal roles in tumor invasion and metastasis. MMP13 (collagenase-3) has been linked to specific malignancies, but its global "pan-cancer" signature—including its genetic drivers and diagnostic potential across all major human cancers—remains under-explored. This study aims to characterize MMP13's role across 33 cancer types and validate its utility as a universal serum diagnostic marker.
Methods
This research integrated large-scale bioinformatics with clinical validation. Data from The Cancer Genome Atlas (TCGA), GTEx, and the Cancer Cell Line Encyclopedia (CCLE) were analyzed to assess MMP13 expression, DNA methylation, and genetic mutations. Survival analyses, including overall survival (OS) and progression-free intervals (PFI), were conducted using GEPIA2 and GSCA. Experimentally, Western blotting was performed on paired human lung adenocarcinoma (LUAD) tissues to evaluate MMP13 and EMT markers (E-cadherin, N-cadherin, vimentin). Finally, serum MMP13 levels were measured via ELISA in 151 samples (27 healthy controls and 124 cancer patients) to evaluate diagnostic efficacy using Area Under the Curve (AUC) analysis.
Key Results
Pan-cancer Expression and Prognosis
Bioinformatics analysis revealed that MMP13 is significantly upregulated in the majority of tumor types compared to normal tissues. This overexpression is primarily driven by DNA hypomethylation and genetic amplifications.
Crucially, high MMP13 mRNA levels significantly predicted poor overall survival (OS) and progression-free intervals in multiple cancers, including kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and adrenocortical carcinoma (ACC).
Tumor Microenvironment and EMT
High MMP13 expression was found to correlate with higher immune and stromal scores but lower tumor purity, suggesting its role in remodeling the extracellular matrix to favor tumor progression. Western blot analysis confirmed that high MMP13 expression in LUAD tissues coincides with a classic EMT signature: decreased E-cadherin and increased N-cadherin and vimentin levels.
Serum Diagnostic Performance
Clinical validation via ELISA demonstrated that serum MMP13 is a superior diagnostic marker. In Head and Neck Squamous Cell Carcinoma (HNSC), MMP13 achieved an AUC of 0.9259, vastly outperforming the standard marker SCC (AUC 0.5321). Similarly, in Breast Invasive Carcinoma (BRCA), MMP13 (AUC 0.8494) outperformed CA15-3 (AUC 0.6718). High diagnostic accuracy was also observed in lung cancers (LUSC AUC 0.8575; LUAD AUC 0.7144).
Discussion and Conclusion
This study establishes MMP13 as a critical oncogene across various cancers, driven by epigenetic and genetic alterations. Its strong association with the EMT pathway and immune infiltration underscores its role in metastasis. Most importantly, the high sensitivity and specificity of serum MMP13 levels suggest its potential as a non-invasive "liquid biopsy" tool for early cancer screening. While limited by sample size, these results warrant larger multi-center clinical trials to standardize MMP13-based diagnostic protocols.
Summary updated